Zobrazeno 1 - 10
of 1 143
pro vyhledávání: '"cdk4/6 inhibitor"'
Autor:
Qi Zhao, Mingxia Jiang, Jiaxuan Liu, Mengqi Zhang, Maiyue He, Shihan Zhou, Jiani Wang, Hongnan Mo, Bo Lan, Peng Yuan, Pin Zhang, Fei Ma, Qiao Li, Binghe Xu
Publikováno v:
Cancer Biology & Medicine, Vol 21, Iss 10, Pp 934-950 (2024)
Objective: CDK4/6 inhibitors (CDK4/6is) in combination with endocrine therapy have secured a central role in the treatment of hormone receptor (HR)-positive advanced breast cancer (ABC) and have transformed the therapeutic landscape. Cross-line CDK4/
Externí odkaz:
https://doaj.org/article/c9c740e3411248cc8774561a0b366f25
Autor:
Zhidong Huang, Kaixin Lou, Mengyang Qi, Jinhui Wang, Linwei Li, Bo Sun, Chen Wang, Xirui Zhou, Debo Chen, Hong Liu
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-16 (2024)
Abstract Background Currently, there is a lack of biomarkers to identify breast cancer (BC) patients who would benefit from CDK4/6 inhibitors. This study combined machine learning (ML) algorithms based on transcriptomic data with both in vivo and in
Externí odkaz:
https://doaj.org/article/9a7d5eea1e1c477ea592e45205347318
Autor:
Krittiyabhorn Kongtanawanich, Sunisa Prasopporn, Supawan Jamnongsong, Nontaphat Thongsin, Tongchai Payungwong, Seiji Okada, Marianne Hokland, Methichit Wattanapanitch, Siwanon Jirawatnotai
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-17 (2024)
Abstract Cancer stem cells (CSC) play an important role in carcinogenesis and are acknowledged to be responsible for chemoresistance in cholangiocarcinoma (CCA). Studying CCA CSC has been challenging, due to lack of consensus CSC markers, and to thei
Externí odkaz:
https://doaj.org/article/f122727f4db34b84928968f66c334b3a
Publikováno v:
Translational Oncology, Vol 49, Iss , Pp 102092- (2024)
CDK4/6 inhibitors combined with endocrine therapy prolonged survival in hormone receptor (HR)-positive and HER2-negative advanced breast cancer. We investigated whether CDK4/6 inhibitors enhance radiosensitivity and their underlying mechanisms of thi
Externí odkaz:
https://doaj.org/article/1de44e4112724428b5c89026680f9140
Autor:
Chaoji Shi, Houyu Ju, Rong Zhou, Shengming Xu, Yunteng Wu, Ziyue Gu, Ying Wang, Wanling Chen, Xinyi Huang, Yong Han, Shuyang Sun, Chuwen Li, Min Wang, Guoyu Zhou, Zhiyuan Zhang, Jiang Li, Guoxin Ren
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Mucosal melanoma (MM) is a rare but devastating subtype of melanoma. Our previous studies have demonstrated robust anti-tumor effects of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors in head and neck MM (HNMM) patient-derived x
Externí odkaz:
https://doaj.org/article/3608e6a7d46a46419f19925324cee8c7
Autor:
Merve Keskinkilic, Mehmet Emin Arayici, Yasemin Basbinar, Hulya Ellidokuz, Tugba Yavuzsen, Ilhan Oztop
Publikováno v:
Breast, Vol 78, Iss , Pp 103815- (2024)
Background: This paper aimed to evaluate the effectiveness of incorporating CDK 4/6 inhibitors (CDK4/6i) into ET for the adjuvant treatment of HR + HER2-resected early-stage breast cancer (ESBC) patients, employing meta-analysis. Methods: In this pap
Externí odkaz:
https://doaj.org/article/330e286730524e79849f3b4010a9a9bd
Autor:
Binliang Liu, Zhe‐Yu Hu, Ning Xie, Liping Liu, Jing Li, Xiaohong Yang, Huawu Xiao, Xuran Zhao, Can Tian, Hui Wu, Jun Lu, Jianxiang Gao, Xuming Hu, Min Cao, Zhengrong Shui, Yu Tang, Quchang Ouyang
Publikováno v:
Cancer Innovation, Vol 3, Iss 6, Pp n/a-n/a (2024)
Abstract Background CDK4/6 inhibitors (CDK4/6i) have shown promising results in the treatment of hormone receptor‐positive (HR+) metastatic breast cancer (MBC) when combined with endocrine therapy (ET). It is crucial to evaluate the actual effectiv
Externí odkaz:
https://doaj.org/article/13b880c7b9a24ee4801deeb38308ad66
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThe combination of CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) is currently the standard first-line treatment for patients with metastatic hormone receptor positive (HR+), and HER2-negative (HER2-) breast cancer. However, the imp
Externí odkaz:
https://doaj.org/article/1a0bc4e2c8114dada25edcc421f7745c
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Objective: Cyclin-dependent kinase (CDK) 4 and 6 inhibitors (abemaciclib, palbociclib and ribociclib) have been recommended in the first-line treatment of hormone receptor-positive (HR+) breast cancer in China. Our study aims to evaluate the efficacy
Externí odkaz:
https://doaj.org/article/0a4ef77523b74d41b2dd5a19467243a7
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionCyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are first-line treatments for hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. With their increasing clinical use, infection-related adverse eve
Externí odkaz:
https://doaj.org/article/d3d9febf06b94f71bcc2ae6139dca011